Edition:
United States

Arena Pharmaceuticals Inc (ARNA.A)

ARNA.A on American Stock Exchange

1.75USD
23 Sep 2016
Change (% chg)

$-0.02 (-1.13%)
Prev Close
$1.77
Open
$1.77
Day's High
$1.77
Day's Low
$1.73
Volume
14,379
Avg. Vol
12,947
52-wk High
$2.65
52-wk Low
$1.30

ARNA.A

Chart for ARNA.A

About

Arena Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing small molecule drugs that target G protein-coupled receptors (GPCRs). The Company's drug, Lorcaserin, is approved for marketing in the United States and South Korea for the indication of weight management, and is... (more)

Overall

Beta: -0.80
Market Cap(Mil.): $423.27
Shares Outstanding(Mil.): 243.26
Dividend: --
Yield (%): --

Financials

  ARNA.A Industry Sector
P/E (TTM): -- 42.52 36.60
EPS (TTM): -0.44 -- --
ROI: -49.06 -0.26 13.91
ROE: -174.68 -3.05 14.82

BRIEF-Arena Pharmaceuticals announces formation of Beacon Discovery Inc

* Announces formation of Beacon Discovery Inc, an independent, privately held drug discovery incubator

Sep 01 2016

BRIEF-Arena Pharmaceuticals, Eisai receive 'paragraph IV certification'

* Co and Eisai Inc have received a 'paragraph IV certification' notification with respect to patents for Belviq

Aug 25 2016

BRIEF-Arena Pharmaceuticals appoints Vincent Aurentz as Chief Business Officer

Aug 15 Arena Pharmaceuticals Inc : Source text for Eikon: Further company coverage:

Aug 15 2016

BRIEF-Arena Pharmaceuticals reports Q2 loss per share $0.11

* Arena Pharmaceuticals reports second quarter 2016 financial results and provides corporate update

Aug 08 2016

BRIEF-Arena Pharma, EISAI announce FDA approval of BELVIQ XR extended-release tablets

* Arena pharmaceuticals inc says in connection with approval, arena will receive a $10 million milestone payment.

Jul 19 2016

BRIEF-Eisai, Arena announce regulatory approval of VENESPRI in Mexico

* Eisai and Arena Pharmaceuticals announce regulatory approval of VENESPRI (lorcaserin HCl) in Mexico

Jul 14 2016

BRIEF-Arena Pharmaceuticals to emphasize on its proprietary clinical stage pipeline

* Arena Pharmaceuticals Inc says strategic shifting of priorities to emphasize its proprietary clinical stage pipeline

Jun 30 2016

BRIEF-Arena Pharmaceuticals Inc announces appointment of Kevin Lind as CFO

* Arena Pharmaceuticals Inc says Kevin R. Lind will join its management team as executive vice president and chief financial officer, effective June 15 Source text for Eikon: Further company coverage:

Jun 15 2016

BRIEF-Arena Pharmaceuticals files for mixed shelf of up to $250 mln

* Arena Pharmaceuticals Inc files for mixed shelf of up to $250 million - SEC filing Source text - (http://1.usa.gov/1tpehJq) Further company coverage:

Jun 14 2016

BRIEF-Arena Pharmaceuticals names Amit Munshi CEO

* Arena Pharmaceuticals announces appointment of Amit D. Munshi as President and Chief Executive Officer Source text for Eikon: Further company coverage:

May 09 2016

Competitors

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : S&P Capital IQ Quantitative Report
$127.00
Provider : Pechala's Reports
$25.00
Provider : Reuters Investment Profile
$20.00
Provider : Thomson Reuters Stock Report
$25.00
Provider : Stock Traders Daily
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.